Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

@article{Debruyne1998SustainedreleaseAF,
  title={Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.},
  author={Frans M. J. Debruyne and Alain Jardin and D. Colloi and Luis Resel and Wim P. J. Witjes and M C Delauche-Cavallier and Christine McCarthy and C Geffriaud-Ricouard},
  journal={European urology},
  year={1998},
  volume={34 3},
  pages={169-75}
}
OBJECTIVES To assess the additive benefit of combining an alpha1-blocker and a 5alpha-reductase inhibitor. METHODS This European, randomized, double-blind, multicenter trial involved 1.051 patients with lower urinary tract symptoms related to benign prostatic hyperplasia. Patients received sustained release (SR) alfuzosin (n = 358), a selective alpha1-blocker given at a dose of 5 mg twice daily without dose titration; finasteride (n = 344), 5 mg once daily, or both drugs (n = 349), for 6… CONTINUE READING